The DOI matches its Crossref record.
Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
Open accessAbstract
When administered in high doses to HIV positive (HIV+) individuals, interleukin 2 (IL-2) causes extreme toxicity and markedly increases plasma HIV levels. Integration of the information from the structure-activity relationships of the IL-2 receptor interaction, the cellular distribution of the different classes of IL-2 receptors, and the pharmacokinetics of IL-2 provides for the rationale that low IL-2 doses should circumvent toxicity. Therefore, to identify a nontoxic, but effective and safe IL-2 treatment regimen that does not stimulate viral replication, doses of IL-2 from 62,500 to 250,000 IU/m2/day were administered subcutaneously for 6 months to 16 HIV+ individuals with 200-500 CD4+ T cells/mm3. IL-2 was already detectable in the plasma of most HIV+ individuals even before therapy. Peak plasma IL-2 levels were near saturating for high affinity IL-2 receptors in 10 individuals who received the maximum nontoxic dose, which ranged from 187,500 to 250,000 IU/m2/day. During the 6 months of treatment at this dose range, plasma levels of proinflammatory cytokines remained undetectable, and plasma HIV RNA levels did not change significantly. However, delayed type hypersensitivity responses to common recall antigens were markedly augmented, and there were IL-2 dose-dependent increases in circulating Natural Killer cells, eosinophils, monocytes, and CD4+ T cells. Expanded clinical trials of low dose IL-2 are now warranted, especially in combination with effective antivirals to test for the prevention of immunodeficiency and the emergence of drug-resistant mutants and for the eradication of residual virions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Self-citationInterleukin 15: biology and relevance to human disease
Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976
Pierson, T., McArthur, J., & Siliciano, R. F. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.665 · Cited by 545
Chun, T.-W., Engel, D., Mizell, S. B., Hallahan, C. W., Fischette, M., Park, S., Davey, R. T., Dybul, M., Kovacs, J. A., Metcalf, J. A., et al. (1999) · Nature Medicine · doi:10.1038/9498 · Cited by 404
Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo
Blattman, J. N., Grayson, J. M., Wherry, E. J., Kaech, S. M., Smith, K. A., & Ahmed, R. (2003) · Nature Medicine · doi:10.1038/nm866 · Cited by 396
Self-citation
Metadata
- Authors
- Jacobson, E. L., Pilaro, F., & Smith, K. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-09-17
- Volume
- 93
- Issue
- 19
- Pages
- 10405-10410
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2054212413
- Cited by
- 163
- References
- 0
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. https://app.cochat.ai/papers/10.1073/pnas.93.19.10405
- The paper
- Jacobson, E. L., Pilaro, F., & Smith, K. A. (1996). Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.93.19.10405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.